Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 225 Binney Street CAMBRIDGE MA 02142 |
Tel: | N/A |
Website: | https://www.biogen.com |
IR: | See website |
Key People | ||
Christopher A. Viehbacher President, Chief Executive Officer, Director | Charles E. Triano Senior Vice President, Head of Investor Relations | Michael R. McDonnell Chief Financial Officer, Executive Vice President |
Ginger Gregory Chief Human Resource Officer, Executive Vice President | Susan H. Alexander Executive Vice President, Chief Legal Officer, Secretary | Rachid Izzar Executive Vice President, Head of Global Product Strategy and Commercialization |
Adam James Keeney Executive Vice President, Head of Corporate Development | Nicole Murphy Executive Vice President - Pharmaceutical Operations and Technology | Priya Singhal Executive Vice President - Head of Development | Robin C. Kramer Senior Vice President, Chief Accounting Officer |
Business Overview |
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ. |
Financial Overview |
For the fiscal year ended 31 December 2023, Biogen Inc revenues decreased 3% to $9.84B. Net income decreased 62% to $1.16B. Revenues reflect Rest of World segment decrease of 9% to $4.11B, United States segment decrease of 9% to $3.14B. Net income also reflects G/L on Invest HFS, Maturity & Trading decrease from $1.51B (income) to $0K, Gain on sale of building decrease from $503.7M (income) to $0K. |
Employees: | 7,570 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $37,336M as of Dec 31, 2023 |
Annual revenue (TTM): | $9,836M as of Dec 31, 2023 |
EBITDA (TTM): | $2,545M as of Dec 31, 2023 |
Net annual income (TTM): | $1,161M as of Dec 31, 2023 |
Free cash flow (TTM): | $1,236M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $5,888M as of Dec 31, 2023 |
Shares outstanding: | 145,360,798 as of Feb 12, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |